Related Experiment Videos
What promise the preliminary tests of coronary artery disease?
Insights
Accurate preliminary tests are crucial for selecting coronary artery disease (CAD) patients for angiography. Current methods fall short, risking delayed life-saving treatment for those needing bypass surgery.
Area of Science:
- Cardiology
- Medical Decision Making
Background:
- Coronary artery disease (CAD) necessitates angiography for surgical planning.
- Many patients with chest pain lack operable CAD, making selective testing essential.
- Current diagnostic tests for CAD lack the required sensitivity.
Purpose of the Study:
- To evaluate the necessity of highly sensitive preliminary tests for coronary artery disease (CAD) before angiography.
- To determine the acceptable false-negative rate for preliminary CAD tests to avoid compromising patient survival.
Main Methods:
- Decision analysis modeling was employed to assess the impact of preliminary test accuracy on patient survival.
- The study analyzed the trade-offs between test sensitivity, specificity, and the risk of denying necessary angiography.
Main Results:
- A false-negative rate below 2% is required for preliminary tests to prevent shortening average patient survival.
- No existing diagnostic procedure currently meets this stringent sensitivity requirement for CAD detection.
- Radionuclide ventriculography shows promise but requires further validation in broader studies.
Conclusions:
- Highly sensitive and accurate preliminary diagnostic tests are vital for identifying patients who will benefit from coronary artery disease (CAD) angiography.
- Current diagnostic strategies may lead to undertreatment of CAD patients due to insufficient test sensitivity.
- Further research and validation of sensitive imaging techniques like radionuclide ventriculography are needed to improve patient selection for CAD interventions.
Abstract:
For some patients with coronary artery disease (CAD), bypass operations prolong life. Angiograms, incurring some risk and considerable expense, are prerequisites to surgical therapy; they delineate the region and extent of disease. However, many people who complain of chest pain do not have disease that can be benefited by operation. Therefore, tests that will safely and economically select the appropriate individuals for angiography are most welcome. Yet, if the preliminary tests falsely declare affected people to be free of CAD, they will deny these patients angiography, and, consequently, surgical treatment that would prolong their lives. Decision analysis determines that a false-negative rate of less than 2% is necessary for tests preliminary to angiography if the average survival of patients is not to be shortened. No currently used procedure has attained this sensitivity. Radionuclide ventriculography approaches this precision, but its sensitivity must be sustained in more broadly based studies.